Kopran Stock Falls to 52-Week Low of Rs.137 Amidst Continued Downtrend

Nov 18 2025 09:56 AM IST
share
Share Via
Kopran, a company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.137 today, marking a significant decline amid a sustained downward trend. The stock has been trading below all major moving averages and has recorded a consecutive six-day fall, reflecting ongoing challenges in its financial performance.



The stock's recent performance shows a decline of 1.04% on the day, underperforming its sector by 0.74%. Over the past six trading sessions, Kopran has delivered a cumulative return of -14.36%, signalling persistent pressure on its share price. This drop comes despite the broader market's mixed movement, with the Sensex opening positively by 91.42 points but subsequently retreating by 381.14 points to trade at 84,661.23, down 0.34% for the day.



In comparison, the Sensex remains close to its 52-week high of 85,290.06, just 0.74% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend for the benchmark index. Kopran, however, is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, highlighting a weaker technical position relative to the broader market.




Holding Kopran from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!



  • Peer comparison ready

  • Superior options identified

  • Cross market-cap analysis


Switch to Better Options →




Examining Kopran's longer-term performance, the stock has delivered a return of -38.07% over the past year, contrasting with the Sensex's positive return of 9.48% during the same period. The stock's 52-week high was Rs.236.10, indicating a substantial decline from its peak. Additionally, Kopran has underperformed the BSE500 index over the last three years, one year, and three months, reflecting a consistent trend of below-par returns.



Financially, Kopran's operating profit has shown a negative compound annual growth rate of -11.79% over the last five years, pointing to challenges in sustaining growth. The company reported a fall in net sales by 22.2% in its September 2025 quarter, which contributed to what has been described as very negative results. This quarter marked the fifth consecutive quarter of negative results for the company, with the previous negative results declared in September 2024 after four consecutive quarters of losses.



Profit after tax (PAT) for the recent quarter stood at Rs. -9.92 crore, representing a decline of 234.4% compared to the corresponding period. Return on capital employed (ROCE) for the half-year was recorded at 5.38%, one of the lowest levels observed. The operating profit to interest coverage ratio for the quarter was -2.53 times, indicating that operating profits were insufficient to cover interest expenses.



Despite Kopran's market size, domestic mutual funds hold a minimal stake of just 0.01%. Given that domestic mutual funds typically conduct detailed research on companies, this small holding may reflect a cautious stance towards the stock's current valuation or business outlook.




Considering Kopran ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!



  • Better options discovered

  • Pharmaceuticals & Biotechnology + beyond scope

  • Top-rated alternatives ready


Compare & Switch Now →




On the balance sheet front, Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, which suggests limited leverage. The company’s ROCE of 4.7% and an enterprise value to capital employed ratio of 1.3 indicate an attractive valuation when compared to its peers' historical averages. However, these valuation metrics coincide with a period of declining profitability, as the company’s profits have fallen by 66.7% over the past year.



In summary, Kopran's stock has reached a new 52-week low of Rs.137 amid a sustained downtrend marked by consecutive quarterly losses, declining sales, and subdued profitability metrics. The stock's technical indicators remain weak relative to the broader market, and its long-term financial data reflects challenges in growth and earnings stability. While the company’s low leverage and valuation metrics provide some context, the overall performance data highlights the difficulties faced by Kopran in recent periods.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News